Drug Trial Radar · NCT06150040
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Sep 11, 2024
Primary completion
Feb 18, 2025
Study completion Feb 18, 2025
Sponsor
- Lead sponsor
- Centre Leon BerardAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NETRIS Pharma
- First posted
- Nov 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with Azacitidine and Venetoclax in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax.
Conditions
- Acute Myeloid Leukemia Refractory
Interventions
NP137Drug
IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
Azacitidine InjectionDrug
Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
VenetoclaxDrug
Orally, 70 mg, every day on Days 1-28
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety run in part : Incidence of Dose Limiting Toxicities (DLT)Time frame: 4 weeks
- Phase II part : Objective Response Rate (ORR)Time frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Léon Bérard
Lyon, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.